Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYX001
MIFTS: 45

Myxopapillary Ependymoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myxopapillary Ependymoma

About this section

MalaCards integrated aliases for Myxopapillary Ependymoma:

Name: Myxopapillary Ependymoma 12 52 58 15 71
Ependymoma Myxopapillary 54

Characteristics:

Orphanet epidemiological data:

58
myxopapillary ependymoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adolescent,All ages,Childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:5075
MeSH 43 D004806
NCIt 49 C3697
SNOMED-CT 67 1623000
ICD10 via Orphanet 33 D43.2
UMLS via Orphanet 72 C0205769
Orphanet 58 ORPHA251643
UMLS 71 C0205769
Sources

Summaries for Myxopapillary Ependymoma

About this section
NIH Rare Diseases : 52 Myxopapillary ependymoma (MEPN) is a slow-growing ependymoma (a type of glioma, which is a tumor that arises from the supportive tissue of the brain and spinal cord). They tend to occur in the lower part of the spinal column and are usually considered to be benign, low-grade or grade I tumors. The age of diagnosis ranges from 6 to 82 years. Symptoms of an ependymoma are related to the location and size of the tumor and may include nausea, vomiting, headache, pain, numbness, bowel or bladder symptoms, and various other signs and symptoms. The cause of ependymomas is unknown. They are known to recur locally (more commonly in individuals diagnosed in childhood). Treatment may vary depending on the location, grade , and whether the tumor has spread to the spine, but typically includes aggressive surgery. Management may also include chemotherapy and radiation therapy .

MalaCards based summary : Myxopapillary Ependymoma, also known as ependymoma myxopapillary, is related to benign ependymoma and cellular ependymoma, and has symptoms including back pain An important gene associated with Myxopapillary Ependymoma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Neuroscience and Spinal Cord Injury. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and skin, and related phenotypes are ependymoma and abnormal conus terminalis morphology

Sources

Related Diseases for Myxopapillary Ependymoma

About this section

Diseases related to Myxopapillary Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 benign ependymoma 32.4 VIM SYP S100B NF2 MUC1 GFAP
2 cellular ependymoma 31.9 SYP RELA C11orf95
3 secretory meningioma 31.2 VIM NF2 MUC1
4 chordoma 31.1 VIM S100B NCAM1 MUC1 GFAP
5 giant cell tumor 30.9 VIM S100B MUC1
6 adenoid cystic carcinoma 30.9 VIM S100B NCAM1 MUC1
7 meningioma, radiation-induced 30.8 VIM S100B NF2 MUC1 GFAP
8 teratoma 30.6 VIM SYP GFAP
9 subependymoma 30.4 SYP NCAM1 GFAP
10 hydrocephalus 30.3 VIM SYP S100B GFAP
11 neurilemmoma 30.2 VIM S100B NF2 MUC1 GFAP
12 meningioma, familial 30.2 SYP NF2 KIAA1549 GFAP
13 paraganglioma 30.1 SYP S100B NCAM1 GFAP
14 neurofibroma 29.8 VIM SYP S100B NF2 MUC1
15 chordoid meningioma 29.6 VIM SYP S100B NCAM1 MUC1 GFAP
16 juvenile pilocytic astrocytoma 29.5 SYP S100B LUC7L2 KIAA1549 GFAP
17 anaplastic ependymoma 29.2 VIM SYP S100B RELA NF2 MUC1
18 spinal cord ependymoma 28.4 YAP1 NF2 LUC7L2 KIAA1549 HOXB13 CTU1
19 rare tumor 10.7
20 back pain 10.7
21 sclerosing perineurioma 10.6 S100B MUC1
22 localized hypertrophic neuropathy 10.6 S100B MUC1
23 reticular perineurioma 10.6 S100B MUC1
24 non-functioning pituitary adenoma 10.6 S100B MUC1
25 aggressive digital papillary adenocarcinoma 10.6 S100B MUC1
26 primitive neuroectodermal tumor of the cervix uteri 10.5 VIM GFAP
27 hydromyelia 10.5 VIM S100B
28 meningeal melanocytoma 10.5 S100B MUC1
29 bednar tumor 10.5 VIM S100B
30 nodular hidradenoma 10.5 VIM MUC1
31 endometrial mucinous adenocarcinoma 10.5 VIM MUC1
32 epithelioid malignant peripheral nerve sheath tumor 10.5 S100B MUC1
33 malignant peritoneal mesothelioma 10.5 NF2 MUC1
34 ovarian serous cystadenofibroma 10.5 NCAM1 MUC1
35 chondroid chordoma 10.5 VIM MUC1
36 pericardial mesothelioma 10.5 VIM MUC1
37 spinal meningioma 10.5
38 cauda equina syndrome 10.5
39 lymphoplasmacyte-rich meningioma 10.5
40 gemistocytic astrocytoma 10.5 S100B GFAP
41 odontogenic myxoma 10.5 VIM S100B
42 reticulum cell sarcoma 10.5 VIM MUC1
43 desmoplastic small round cell tumor 10.5 VIM MUC1
44 biphasic synovial sarcoma 10.5 VIM MUC1
45 traumatic brain injury 10.5 S100B GFAP
46 myopericytoma 10.4 S100B RELA
47 intracranial cysts 10.4 S100B MUC1 GFAP
48 embryonal sarcoma 10.4 VIM S100B
49 syringocystadenoma papilliferum 10.4 S100B MUC1 GFAP
50 orbital cancer 10.4 NF2 NCAM1

Graphical network of the top 20 diseases related to Myxopapillary Ependymoma:



Diseases related to Myxopapillary Ependymoma
Sources

Symptoms & Phenotypes for Myxopapillary Ependymoma

About this section

Human phenotypes related to Myxopapillary Ependymoma:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ependymoma 58 31 obligate (100%) Obligate (100%) HP:0002888
2 abnormal conus terminalis morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0031938
3 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
4 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
5 unsteady gait 58 31 frequent (33%) Frequent (79-30%) HP:0002317
6 abnormal large intestine physiology 58 31 frequent (33%) Frequent (79-30%) HP:0012700
7 autonomic bladder dysfunction 58 31 frequent (33%) Frequent (79-30%) HP:0005341
8 neck pain 58 31 frequent (33%) Frequent (79-30%) HP:0030833
9 neoplasm of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0008069
10 abnormal sacrum morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0005107
11 abnormality of the auditory canal 58 31 very rare (1%) Very rare (<4-1%) HP:0000372
12 neoplasm of the central nervous system 58 Frequent (79-30%)

UMLS symptoms related to Myxopapillary Ependymoma:


back pain

MGI Mouse Phenotypes related to Myxopapillary Ependymoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 CA2 GFAP HOXB13 HOXB5 NCAM1 NF2
Sources

Drugs & Therapeutics for Myxopapillary Ependymoma

About this section

Drugs for Myxopapillary Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
6 Nootropic Agents Phase 3
7 Cholinergic Agents Phase 3
8 Cholinesterase Inhibitors Phase 3
9 Liver Extracts Phase 3
10 Cola Phase 3
11 Narcotics Phase 3
12 Anesthetics Phase 3
13 Anesthetics, General Phase 3
14 Analgesics, Opioid Phase 3
15 Adjuvants, Anesthesia Phase 3
16 Central Nervous System Depressants Phase 3
17 Anesthetics, Intravenous Phase 3
18 Analgesics Phase 3
19 Neurotransmitter Agents Phase 3
20 Dopamine Uptake Inhibitors Phase 3
21 Central Nervous System Stimulants Phase 3
22 Dexmethylphenidate Hydrochloride Phase 3
23 Dopamine Agents Phase 3
24
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
25
Etoposide Approved Phase 2 33419-42-0 36462
26
Tamoxifen Approved Phase 2 10540-29-1 2733526
27
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
28
Sodium citrate Approved, Investigational Phase 2 68-04-2
29
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
30
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
31
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
32
leucovorin Approved Phase 2 58-05-9 6006 143
33
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
34
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
35
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
36
Iodine Approved, Investigational Phase 2 7553-56-2 807
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
38
Acetaminophen Approved Phase 2 103-90-2 1983
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
40
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
41
Promethazine Approved, Investigational Phase 2 60-87-7 4927
42
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
44 Etoposide phosphate Phase 2
45 Topoisomerase Inhibitors Phase 2
46 Antineoplastic Agents, Immunological Phase 1, Phase 2
47 Hormones Phase 2
48 Estrogens Phase 2
49 topoisomerase I inhibitors Phase 2
50 Selective Estrogen Receptor Modulators Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
5 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
6 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
7 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
8 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
9 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
10 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
11 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
12 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
13 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
14 Defining Functional Tissue in Brain Tumors With Integrated Neuroimaging (Pilot Study) Withdrawn NCT00005083 Phase 2
15 Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
16 PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS Completed NCT00002753 Phase 1
17 Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration Completed NCT00401024 Phase 1 imatinib mesylate
18 A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas Completed NCT00036894 Phase 1 lenalidomide
19 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
20 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
21 Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
22 A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors Completed NCT00544284 Phase 1 bortezomib;temozolomide
23 Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones Completed NCT00730613 Phase 1
24 A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
25 A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carboplatin in Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
26 A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
27 A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00006368 Phase 1
28 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
29 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat
30 Mutant MGMT Gene Transfer Into Human Hematopoietic Progenitors to Protect Hematopoiesis During O6-Benzylguanine (BG, NSC 637037) and Carmustine Followed by Temozolomide Therapy of Advanced Solid Tumors Terminated NCT00003567 Phase 1 O6-benzylguanine;carmustine;temozolomide
31 Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis Completed NCT00967200
32 Temozolomide Induced Changes in Semen/Sperm Analysis in Men With Newly Diagnosed, Progressive or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
33 Prospective Study on the Short-Term Adverse Effects From Gamma Knife Radiosurgery Completed NCT00255671
34 Magnetic Resonance Correlates of Glioma Tumor Burden Completed NCT00005082
35 San Francisco Bay Area Adult Glioma Prognosis Study Protocol Completed NCT01009307
36 Exploring Outcomes and Risk in Patients With Rare Central Nervous System Tumors Recruiting NCT03251989
37 Perfusion Magnetic Resonance Imaging of Brain Tumors: Correlation With Indicators of Angiogenesis Withdrawn NCT00005790

Search NIH Clinical Center for Myxopapillary Ependymoma

Sources

Genetic Tests for Myxopapillary Ependymoma

About this section
Sources

Anatomical Context for Myxopapillary Ependymoma

About this section

MalaCards organs/tissues related to Myxopapillary Ependymoma:

40
Brain, Spinal Cord, Skin, Temporal Lobe, Bone, Lung, Liver
Sources

Publications for Myxopapillary Ependymoma

About this section

Articles related to Myxopapillary Ependymoma:

(show top 50) (show all 334)
# Title Authors PMID Year
1
Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. 54 61
19521276 2009
2
An immunohistochemical comparison of chordoma with renal cell carcinoma, colorectal adenocarcinoma, and myxopapillary ependymoma: a potential diagnostic dilemma in the diminutive biopsy. 54 61
7504258 1993
3
Molecular characterization of histopathological ependymoma variants. 61
31679042 2020
4
Resection of Myxopapillary Ependymoma of the Filum Terminale: 2-Dimensional Operative Video. 61
31073602 2020
5
Subcutaneous sacrococcygeal myxopapillary ependymoma misdiagnosed as pilonidal disease. 61
31900294 2020
6
Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. 61
31989347 2020
7
Filum Terminale Ependymoma in an Infant with Meningocele. 61
31962322 2020
8
Long-Term Surgical Resection Outcomes of Pediatric Myxopapillary Ependymoma: Experience of Two Centers and Brief Literature Review. 61
31899399 2019
9
TERTp Mutation Detection in Plasma by Droplet-Digital Polymerase Chain Reaction in Spinal Myxopapillary Ependymoma with Lung Metastases. 61
31330336 2019
10
Spinal Myxopapillary Ependymoma: The Sapienza University Experience and Comprehensive Literature Review Concerning the Clinical Course of 1602 Patients. 61
31152881 2019
11
Myxopapillary ependymoma of the sacrum. 61
31555979 2019
12
Myxopapillary ependymoma of cauda equina presented with communicating hydrocephalus and papilloedema: A case report. 61
31424046 2019
13
[Superficial siderosis of the central nervous system caused by myxopapillary ependymoma of conus medullaris and cauda equine: a case report and literature review]. 61
31420638 2019
14
Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas. 61
31473875 2019
15
Management and Outcome Analysis of Conus and Filum ependymoma: A Tertiary Center Study. 61
31497108 2019
16
Benign ependymoma with extensive intracranial and spinal cerebrospinal fluid dissemination: case report and literature review. 61
28633540 2019
17
Invasive myxopapillary ependymoma of the lumbar spine: A case report. 61
31183345 2019
18
Myxopapillary Ependymoma. 61
30844350 2019
19
Intradural Extramedullary Spinal Neoplasms: Radiologic-Pathologic Correlation. 61
30844353 2019
20
Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. 61
31850213 2019
21
A rare case of an intramedullary metastasis of a myxopapillary ependymoma. 61
31528421 2019
22
Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature. 61
30321682 2019
23
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. 61
30053291 2018
24
Isolated myxopapillary ependymoma of the fourth ventricle: case report and review of literature. 61
30317890 2018
25
Pediatric extraspinal sacrococcygeal ependymoma (ESE): an Italian AIEOP experience of six cases and literature review. 61
29725826 2018
26
Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. 61
29270703 2018
27
Myxopapillary Ependymoma of Lumbar Soft Tissue: A Case Report With Gene Expression Evaluation. 61
29254456 2018
28
Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. 61
29380114 2018
29
Unusual paediatric spinal myxopapillary ependymomas: Unique molecular entities or pathological variations on a theme? 61
29402569 2018
30
[Presacral lesion at the rima ani]. 61
29018939 2018
31
Teaching Case 2-2018: Sclerosing myxopapillary ependymoma mimicking whorling-sclerosing meningioma. 61
29436365 2018
32
Metastases of spinal myxopapillary ependymoma: unique characteristics and clinical management. 61
29219779 2018
33
Myxopapillary ependymoma with anaplastic features: A case report with review of the literature. 61
30294495 2018
34
An Extremely Rare Case of Back and Hip Pain due to the Metastasis of Late Recurrent Myxopapillary Ependymoma to the Inguinal Lymph Node. 61
29166763 2018
35
Unusual cauda equina syndrome due to multifocal ependymoma infiltrated by lymphoma. 61
29354750 2017
36
Sporadic NF2 Mosaic: Multiple spinal schwannomas presenting with severe, intractable pain following pregnancy. 61
29780700 2017
37
Spinal myxopapillary ependymoma presenting with low back pain and subarachnoid hemorrhage. 61
28737370 2017
38
Occipital Intraparenchymal Myxopapillary Ependymoma: Case Report and Literature Review. 61
29114296 2017
39
You're the Flight Surgeon. 61
28923150 2017
40
Characterization of gliomas: from morphology to molecules. 61
28674742 2017
41
Anaplastic myxopapillary ependymoma in an infant: Case report and literature review. 61
28580214 2017
42
Primary Seeding of Myxopapillary Ependymoma: Different Disease in Adult Population? Case Report and Review of Literature. 61
28040529 2017
43
Solitary aneurysm of the filum terminale artery: A case report and review of the literature. 61
28868191 2017
44
Primary multifocal myxopapillary ependymoma of the filum terminale. 61
26154385 2016
45
Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. 61
27423644 2016
46
Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. 61
27306443 2016
47
Outcome Analysis in Cases of Spinal Conus Cauda Ependymoma. 61
27790509 2016
48
Spinal myxopapillary ependymoma with interval drop metastasis presenting as cauda equina syndrome: case report and review of literature. 61
27757435 2016
49
Lumbar corpectomy for correction of degenerative scoliosis from osteoradionecrosis reveals a delayed complication of lumbar myxopapillary ependymoma. 61
27056674 2016
50
Intradural extramedullary non-myxopapillary ependymoma with a lumbar nerve root involvement in a Japanese man. 61
26852964 2016
Sources

Variations for Myxopapillary Ependymoma

About this section
Sources

Expression for Myxopapillary Ependymoma

About this section
Search GEO for disease gene expression data for Myxopapillary Ependymoma.
Sources

Pathways for Myxopapillary Ependymoma

About this section

Pathways related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.97 SYP S100B NF2 NCAM1 GFAP CA2
2
Spinal Cord Injury 1
11.51 VIM PLA2G5 GFAP
3
Signaling by ERBB4 65
Show member pathways
 11.37 YAP1 S100B GFAP
4
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
10.92 VIM SYP S100B NCAM1 GFAP
Sources

GO Terms for Myxopapillary Ependymoma

About this section

Biological processes related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of neuronal synaptic plasticity GO:0048168 9.37 SYP S100B
2 intermediate filament organization GO:0045109 9.32 VIM GFAP
3 astrocyte development GO:0014002 9.26 VIM GFAP
4 Bergmann glial cell differentiation GO:0060020 9.16 VIM GFAP
5 regulation of stem cell proliferation GO:0072091 8.96 YAP1 NF2
6 intermediate filament-based process GO:0045103 8.62 VIM GFAP
Sources

Sources for Myxopapillary Ependymoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....